BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26797085)

  • 61. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
    BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Brenner tumor].
    Karseladze AI
    Arkh Patol; 1987; 49(5):40-6. PubMed ID: 3619690
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular genetics of ovarian carcinomas.
    Diebold J
    Histol Histopathol; 1999 Jan; 14(1):269-77. PubMed ID: 9987671
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms.
    Kanter M; Turan G; Usta C; Usta A; Esen HH; Tavlı L; Celik C; Demirkol Y; Kanter B
    J Mol Histol; 2016 Apr; 47(2):145-52. PubMed ID: 26815661
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy].
    Staebler A; Diebold J
    Pathologe; 2007 May; 28(3):180-6. PubMed ID: 17431628
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
    Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
    Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
    [TBL] [Abstract][Full Text] [Related]  

  • 67. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients.
    Cuatrecasas M; Erill N; Musulen E; Costa I; Matias-Guiu X; Prat J
    Cancer; 1998 Mar; 82(6):1088-95. PubMed ID: 9506354
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pure and mixed Brenner tumors of the ovary: clinicopathologic and histogenetic observations.
    Waxman M
    Cancer; 1979 May; 43(5):1830-9. PubMed ID: 445369
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
    Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
    PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Brenner tumor of the ovary--a clinicopathological report of 5 cases].
    Li AY; Li XL; Xing LY
    Zhonghua Zhong Liu Za Zhi; 1987 May; 9(3):218-220, 10. PubMed ID: 3447865
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.
    McDaniel AS; Stall JN; Hovelson DH; Cani AK; Liu CJ; Tomlins SA; Cho KR
    JAMA Oncol; 2015 Nov; 1(8):1128-32. PubMed ID: 26181193
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Primary retroperitoneal mucinous cystic neoplasm of borderline malignancy with
    Son SM; Woo CG; Yun SJ; Lee OJ
    J Int Med Res; 2023 May; 51(5):3000605231172469. PubMed ID: 37198972
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
    Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
    PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors.
    Sieben NL; Oosting J; Flanagan AM; Prat J; Roemen GM; Kolkman-Uljee SM; van Eijk R; Cornelisse CJ; Fleuren GJ; van Engeland M
    J Clin Oncol; 2005 Oct; 23(29):7257-64. PubMed ID: 16087957
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Detecting KRAS mutations in pancreatic cystic neoplasms: droplet digital PCR versus targeted next-generation sequencing.
    van Huijgevoort NCM; Halfwerk HBG; Lekkerkerker SJ; Reinten RJ; Ramp F; Fockens P; Besselink MG; Busch OR; van Noesel CJM; van de Vijver MJ; Verheij J; van Hooft JE; Dijk F
    HPB (Oxford); 2023 Jan; 25(1):155-159. PubMed ID: 36328896
    [No Abstract]   [Full Text] [Related]  

  • 77. Three cases of an unusual pattern of invasion in malignant Brenner tumors.
    St Pierre-Robson K; Dunn PJ; Cooper E; Tofazzal N; Hirschowitz L; McCluggage WG; Ganesan R
    Int J Gynecol Pathol; 2013 Jan; 32(1):31-4. PubMed ID: 23202779
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
    Jamieson S; Alexiadis M; Fuller PJ
    Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.
    Hunter SM; Gorringe KL; Christie M; Rowley SM; Bowtell DD; ; Campbell IG
    Clin Cancer Res; 2012 Oct; 18(19):5267-77. PubMed ID: 22891197
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
    Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
    Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.